Tamoxifen alone + Tamoxifen + Aminoglutethimide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Early-stage Breast Cancer
Conditions
Early-stage Breast Cancer
Trial Timeline
Dec 1, 1990 → Mar 1, 2000
NCT ID
NCT00309491About Tamoxifen alone + Tamoxifen + Aminoglutethimide
Tamoxifen alone + Tamoxifen + Aminoglutethimide is a phase 3 stage product being developed by AstraZeneca for Early-stage Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00309491. Target conditions include Early-stage Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00309491 | Phase 3 | Completed |
Competing Products
9 competing products in Early-stage Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| ICG | Johnson & Johnson | Pre-clinical | 23 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| UCB0599 + Placebo | UCB | Phase 2 | 49 |
| Rasagiline + Pramipexole | Lundbeck | Approved | 82 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 44 |